Autologous muscle derived stem cell therapy - Cook MyoSite

Drug Profile

Autologous muscle derived stem cell therapy - Cook MyoSite

Alternative Names: AMDC - Cook MyoSite; AMDC-USR; Autologous muscle derived cells - Cook MyoSite; Autologous muscle derived stem cells - Cook MyoSite; CMI-AMDC

Latest Information Update: 14 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cook MyoSite
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Stress incontinence
  • Phase II Bladder dysfunction
  • Phase I/II Faecal incontinence
  • Discontinued Ischaemic heart disorders

Most Recent Events

  • 12 Apr 2017 Cook MyoSite in collaboration with Quintiles plans a phase III trial for Stress incontinence (NCT03104517)
  • 29 Jan 2017 Cook MyoSite completes a phase III trial in Stress incontinence in United Kingdom, Canada and Germany (NCT01382602)
  • 01 Dec 2014 Cook initiates enrolment in a phase I/II trial for Stress incontinence in USA (NCT02291432)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top